The US-based medical technology company has designed Zoom 88 Support to bring the benefits of intracranial access to more stroke patients
FDA clears Imperative Care’s Zoom 88 LDP Support. (Credit: The U.S. Food and Drug Administration/Wikimedia Commons)
Imperative Care has received 510(k) clearance from the US Food and Drug Administration (FDA) for its Zoom 88 Large Distal Platform (LDP) Support.
The US-based medical technology company has designed Zoom 88 Support to bring the benefits of intracranial access to more stroke patients. It is a portfolio expansion of the firm’s Zoom 88 Large Distal Platform.
Imperative Care said that it has used large-bore .088″ intracranial access combined with angled-tip aspiration catheters to facilitate better and quicker reperfusion for stroke operations.
Zoom 88 Support also expands Imperative Care’s .088″ intracranial access portfolio, which is said to be the only access portfolio on the market to support large-bore intracranial access.
The existing Zoom 88 LDP and Zoom RDL Access Platform are also included in the portfolio.
Imperative Care said that the Zoom Stroke Solution comes with a Zoom Pump with Zoom POD for sterile-field clot capture and four vessel-compatible Zoom Aspiration Catheters with a special slanted tip for improved clot ingestion.
By incorporating a newly developed support profile, Zoom 88 Support gives doctors even more control over their thrombectomy procedures across a wider patient base while maintaining the potential of .088″ intracranial access with added stability.
Imperative Care stroke business GM Ariel Sutton said: “Zoom 88 Support was purposefully designed to meet the needs of more patients and deliver on the feedback we’ve received from physicians. Zoom 88 Support provides the same benefits of intracranial access found with Zoom 88 LDP, with the ability to treat more proximal or tandem occlusions.
“With the introduction of Zoom 88 Support, we continue to grow our patient-first portfolio to bring the benefits of large-bore intracranial access to more people.”
Additionally, the medical technology firm said that it has successfully completed the initial cases using Zoom 88 Support.
The system was used to treat an acute stroke in a patient who had a tandem occlusion and needed intracranial access with greater proximal support.
In the case, Zoom 88 Support offered .088” intracranial access from the femoral artery, enabling the treatment of distal occlusion using a Zoom Aspiration Catheter.
In addition, the system provided a stable platform for treating the proximal occlusion, which led to complete TICI 3 revascularisation.